Solara Active Pharma Sciences Receives Funds from Rights Issue, Converts Partly Paid-Up Shares
Solara Active Pharma Sciences Limited reported the receipt of the second and final call money for its rights equity shares, confirming a significant capital infusion and subsequent conversion of partly paid-up shares.The company previously intimated the making of the Second and Final Call of Rs. 112.50 per Rights Equity Share on the outstanding partly paid-up equity shares. These shares had a face value of Rs. 10.00 each, with Rs. 7.00 paid up, and were originally allotted on a rights basis on June 19, 2024.
Solara Active Pharma Sciences informed stakeholders that it received the Second and Final Call money aggregating to Rs. 1,29,94,28,775.00. This sum was received against 1,15,50,478 rights equity shares, with each share valued at Rs. 112.50.
Following the successful collection of funds, the Company's Rights Issue Committee, meeting on May 15, 2026, approved the conversion of the 1,15,50,478 partly paid-up equity shares (bearing ISIN IN9624Z01022) into fully paid-up equity shares (bearing ISIN INE624Z01016).
The corporate action involves converting the partly paid-up shares with a face value of Rs. 10.00 each and Rs. 7.00 paid-up into fully paid-up equity shares with a face value of Rs. 10.00 each and Rs. 10.00 paid-up.
As of the date of the report, the total paid-up capital of Solara Active Pharma Sciences Limited stands at Rs. 47,98,12,464.50.
The current paid-up capital structure is detailed below:
| Share Type | Number of Shares | Paid-up Value per Share |
|---|---|---|
| Fully Paid-Up Equity Shares | 4,77,25,485 | Rs. 10.00 |
| Partly Paid-Up Equity Shares | 2,82,470 | Rs. 7.00 |
| Partly Paid-Up Equity Shares | 1,65,807 | Rs. 3.50 |
SOLARA Stock Price Movement
Shares of Solara Active Pharma Sciences Limited are rallying robustly to ₹575.05 as of 2:35 PM, climbing 13.27% in live trading, up ₹67.35 today. This strong upward momentum is supported by significant trading activity, with the stock moving on a volume of 3.11 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.